大行评级|高盛:下调石药集团目标价至7.84港元 维持“买入”评级

格隆汇
02 Apr

高盛发表研报指,石药集团去年第四季业绩如预期般疲软,去库存影响加深及持续的集采是主要原因。公司去年第四季销售63.2亿元,按年降16.6%,其中成品药销售额按年降20%。肿瘤药品销售按年降61%尤为疲弱,受多美素和津优力因集采影响。

该行因应研发费用增加,下调对公司今明两年盈利预测5.2%和5.8%,目标价由8.52港元降至7.84港元,维持“买入”评级。该行引述管理层指,公司今年恢复增长,受惠低基数及2021年后推出的新药带来约15亿元的增量销售。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10